THROMBOSPONDIN-1 POLYPEPTIDES AND METHODS OF USING SAME

1 . A polypeptide comprising a thrombospondin-1 (TSP-1) domain, or portion thereof, and a fragment crystallizable (Fc) region.

2 . The polypeptide of claim 1 , wherein said TSP-1 domain, or portion thereof, is a type 1 repeat (TSR) domain, or portion thereof.

3 . The polypeptide of claim 2 , wherein said TSR domain, or portion thereof, is a TSR domain, or portion thereof, of human TSP-1.

4 . The polypeptide of claim 3 , wherein the amino acid sequence of said TSR domain, or portion thereof, of human TSP-1 comprises an amino acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1-7.

5 . The polypeptide of claim 1 , wherein said Fc region comprises a CH2 domain and a CH3 domain.

6 . The polypeptide of claim 5 , wherein said CH2 domain and said CH3 domain are heavy chain constant domains of an immunoglobulin selected from the group consisting of IgG1, IgG2, IgG3, and IgG4.

7 . The polypeptide of claim 1 , wherein said TSP-1 domain, or portion thereof, and said Fc region are positioned relative to each other in an N-terminal to C-terminal direction as follows: X-TSP-1 domain-Y-Fc region-Z,

wherein each of X, Y, and Z is absent or is an amino acid sequence of at least one amino acid.

8 . The polypeptide of claim 1 , wherein said TSP-1 domain, or portion thereof, and said Fc region are positioned relative to each other in an N-terminal to C-terminal direction as follows: X-Fc region-Y-TSP-1 domain-Z,

wherein each of X, Y, and Z is absent or is an amino acid sequence of at least one amino acid.

9 . The polypeptide of claim 1 , wherein said Fc region is conjugated to a functional moiety.

10 . A polynucleotide encoding a polypeptide of claim 1 .

11 . A vector comprising the polynucleotide of claim 10 .

12 . A host cell comprising the vector of claim 11 .

13 . A method of producing a polypeptide of claim 1 , said method comprising culturing said host cell of claim 12 in a culture medium.

14 . A composition comprising the polypeptide of claim 1 .

15 . A method of treating a subject having a disorder associated with pathological angiogenesis comprising administering a therapeutically effective amount of the composition of claim 14 to said subject, thereby treating said subject.

16 . A method of treating a subject having a disorder associated with pathological angiogenesis comprising administering a therapeutically effective amount of a composition, wherein said composition comprises a polypeptide comprising an amino acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 1-7 or a polynucleotide encoding said polypeptide.

17 . The method of claim 15 or 16 , wherein said disorder is cancer.

18 . The method of claim 17 , wherein said cancer is epithelial ovarian cancer (EOC).

19 . The method of claim 15 or 16 , wherein said composition is administered intramuscularly, intravenously, intradermally, percutaneously, intraarterially, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostatically, intrapleurally, intratracheally, intranasally, intravitreally, intravaginally, intrarectally, topically, intratumorally, peritoneally, subcutaneously, subconjunctivally, intravesicularlly, mucosally, intrapericardially, intraumbilically, intraocularly, orally, topically, locally, by inhalation, by injection, by infusion, by continuous infusion, by localized perfusion bathing target cells directly, by catheter, by lavage, in cremes, or in lipid compositions.

20 . A kit comprising:

(a) the composition of claim 14 ; and

(b) instructions for administering said composition to a subject to treat a disorder associated with pathological angiogenesis.